Clinical Trials Logo

Clinical Trial Summary

To investigate the effect of allogeneic SLET and re-epithelialization after allogeneic SLET.


Clinical Trial Description

Simple limbal epithelial transplantation (SLET) was introduced in 2012 by Sangwan and coworkers to overcome the issues mainly related to the cost of a GMP-certified product and ease of surgical manipulations that al- lows use of smaller pieces of limbus from the contralateral eye (thus avoiding iatrogenic problems). A completely epithelialized, avascular and stable corneal surface was achieved by 6 weeks and was maintained in all recipient eyes at a mean follow-up of 9.2 ± 1.9 months. Best corrected visual acuity improved from worse than 20/200 in all recipient eyes before surgery to 20/40 or better in four (66.6%) eyes. None of the donor eyes developed any complications.Basu et al. reported autologous SLET on a population of 125 patients which included 65 adults and 60 children suffering from unilateral LSCD. 76% (95/125) of eyes maintained a successful outcome at final follow-up without progressive conjunctivalization, development of persistent epithelial defect, infection, or need for repeat SLET. Survival probability of 80% in adults and 72% in children after 1 year. So far, most of the reports have been about autoSLET, that is, the limbal explants are obtained from the unaffected eye of the same recipient, avoiding immune reaction at the later stage. Also, they demonstrated SLET had promising result both in adults and children. A study by Iyer and coworkers used alloSLET in early stages after ocular chemical injury to achieve rapid epithelialization. Instead of taking the biopsy from the recipient's healthy eye, they took it from a cadaveric donor and performed the SLET. Epithelialization and improved best corrected visual acuity and corneal phenotype were achieved at early stages; however, 7 of 18 eyes had a gradual failure of the allograft, and 5 eyes underwent subsequent limbal autograft. Symblepheron formation involving one to two quadrants was recorded in 3 eyes (16.7%). Visual rehabilitative procedures in the chronic phase of chemical injury, in most instances after alloSLET in the acute stage, did not require any keratoplasties. Unfortunately, most diseases causing limbal deficiency, e.g., surface burns (alkali/ thermal), Stevens-Johnson syndrome, contact lens-related epitheliopathy, and ocular cicatricial pemphigoid, tend to affect both eyes of a patient. Autologous SLET may not be applicable in patients with bilateral eyes involvement. In this study, the effect of allogeneic SLET will be investigated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04021134
Study type Observational
Source National Taiwan University Hospital
Contact Wei-Li Chen, phD
Phone +886223123456
Email cwlntuh@gmail.com
Status Recruiting
Phase
Start date July 5, 2019
Completion date July 1, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT03957954 - Stem Cell Therapy for Limbal Stem Cell Deficiency Phase 1
Recruiting NCT05909735 - Treatment of LSCD With DM Phase 1
Completed NCT03594370 - Multiple Noninvasive Examination Modality to Evaluate the Severity of Ocular Surface Disorders
Recruiting NCT04021875 - The Effects of Autologous SLET
Completed NCT03226015 - Autologous Oral Mucosa Transplantation for Limbal Stem Cell Deficiency N/A
Recruiting NCT04995926 - Labial Mucosal Epithelium Grafting for Corneal Limbus Substitution N/A
Completed NCT05461469 - CDL Validation Study
Completed NCT02415218 - Transplantation of Autologous Oral Mucosal Epithelial Sheets for Limbal Stem-cell Deficiency Phase 1/Phase 2
Not yet recruiting NCT03884569 - Cultivated Limbal Epithelial Transplantation (CLET) for Limbal Stem Cell Deficiency (LSCD)